Marwah Medicine

INICET, Medical, Medicine, Medicine classes, NExT, NExT Exam

FDA Approves First Oral Drug for Dermatomyositis

Brepocitinib (Lisraya) Explained: Mechanism, VALOR Trial, Dose, Safety & Exam Pearls By Dr Deepak Marwah  |  Marwah Medicine A major change has arrived in dermatomyositis treatment. On August 27, 2026, the US FDA approved brepocitinib (Lisraya) tablets for adults with dermatomyositis, making it the first FDA-approved oral treatment specifically indicated for adult dermatomyositis. HIGH-YIELD ONE-LINER Brepocitinib = oral selective TYK2-JAK1 inhibitor → adult dermatomyositis. For medical students, that one line may be enough to answer a future NEET-PG, INI-CET or FMGE update question. For clinicians, however, the story is more interesting: the Phase 3 VALOR trial showed meaningful improvement in overall dermatomyositis activity, skin disease, physical function and glucocorticoid tapering with the 30-mg dose. Why this approval matters Dermatomyositis is a systemic autoimmune inflammatory myopathy. The classic teaching focuses on proximal muscle weakness, heliotrope rash and Gottron papules, but clinically the disease may involve skin, muscle, joints, lungs and other organs. Treatment has traditionally relied heavily on glucocorticoids and other immunomodulatory therapies, many used off-label. A specifically approved oral targeted therapy therefore represents an important change in the treatment landscape. What exactly is brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1. These kinases participate in intracellular cytokine signaling pathways involved in immune activation and inflammation. Think of the pathway as: Cytokine signal → JAK/TYK signaling → inflammatory gene signaling → immune-mediated tissue injury. By inhibiting TYK2 and JAK1, brepocitinib modifies several inflammatory signaling pathways implicated in dermatomyositis. The study behind the approval: VALOR The pivotal evidence came from the Phase 3 VALOR trial, a double-blind randomized placebo-controlled study involving 241 adults with dermatomyositis. Participants received brepocitinib 30 mg once daily, brepocitinib 15 mg once daily, or placebo for 52 weeks. Background standard therapies were continued and glucocorticoids were tapered. What did the trial show? Group Mean Total Improvement Score at Week 52 Brepocitinib 30 mg 46.5 Brepocitinib 15 mg 37.5 Placebo 31.2 The 30-mg dose was significantly superior to placebo for the primary endpoint. Importantly, brepocitinib 30 mg was also superior across all nine key secondary endpoints, including skin disease activity, systemic glucocorticoid tapering and functional disability. Improvements in some outcomes were observed as early as week 4. It was not just about muscle enzymes One of the clinically attractive aspects of the VALOR results is that benefit was not restricted to a laboratory value. Dermatomyositis can produce persistent and troublesome cutaneous disease even when muscle manifestations are less dramatic. The 30-mg dose demonstrated improvement across clinically relevant domains including skin activity and physical function. The steroid-sparing angle Long-term glucocorticoid exposure carries substantial toxicity, including diabetes, osteoporosis, infection risk, cataracts, hypertension and weight gain. In VALOR, improvement with brepocitinib 30 mg was accompanied by greater glucocorticoid tapering. This makes the result clinically more meaningful than a change in a single disease marker. Does this replace steroids? No. The approval should not be interpreted as meaning that every newly diagnosed patient can simply replace conventional therapy with one tablet. Dermatomyositis is heterogeneous. Treatment decisions still depend on the severity and pattern of muscle disease, dysphagia, respiratory involvement, interstitial lung disease, skin disease, autoantibody profile, malignancy evaluation, previous treatment response and patient-specific risks. Also remember an important trial detail: standard therapies were continued while glucocorticoids were tapered. Brepocitinib adds a new targeted option; it does not erase the need for individualized specialist management. Dose: the number worth remembering The FDA-approved Lisraya tablet contains brepocitinib 30 mg, administered orally once daily for adults with dermatomyositis. Safety: oral does not mean casual Brepocitinib is a potent immunomodulatory therapy. In VALOR, serious infections occurred more frequently with brepocitinib 30 mg than with placebo (10% versus 1%). The FDA prescribing information contains important warnings and precautions, including serious infections, malignancy, major adverse cardiovascular events and thrombosis. Common adverse reactions reported in the FDA medication information include upper respiratory tract infections, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, falls, influenza and acne. Clinical message: “Oral” should never be confused with “low-risk.” Appropriate patient selection, screening and monitoring remain essential. What should medical students remember? Drug: Brepocitinib Trade name: Lisraya Route: Oral, once daily Dose: 30 mg once daily Mechanism: Selective TYK2-JAK1 inhibitor Indication: Dermatomyositis in adults FDA approval: August 27, 2026 Key trial: VALOR Potential exam question A patient with dermatomyositis is started on a newly FDA-approved oral therapy that selectively inhibits TYK2 and JAK1. Which drug is most likely being prescribed? Answer: Brepocitinib (Lisraya). The bigger lesson: targeted therapy is entering myositis For years, dermatomyositis was taught through its memorable clinical signs: heliotrope rash, Gottron papules and proximal muscle weakness. Those remain fundamental. But modern medicine increasingly asks a second question: which molecular pathways are driving the disease, and can those pathways be targeted? Brepocitinib represents that transition from broad immunosuppression toward more targeted immune modulation. Its ultimate place in treatment algorithms will continue to evolve with real-world experience, longer-term safety data, accessibility and cost. But the 2026 approval itself is already an important milestone in dermatomyositis therapy. Frequently Asked Questions What is the new oral drug for dermatomyositis? Brepocitinib, marketed as Lisraya, was FDA-approved in August 2026 for the treatment of dermatomyositis in adults. What is the mechanism of brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1, modifying cytokine signaling involved in inflammatory and autoimmune pathways. What is the dose of brepocitinib for dermatomyositis? The FDA-approved Lisraya dose is 30 mg orally once daily. Is brepocitinib a JAK inhibitor? Yes. Brepocitinib selectively inhibits TYK2 and JAK1. Is brepocitinib better than steroids for dermatomyositis? The treatments should not be reduced to a simple either-or comparison. In VALOR, background standard therapies were continued while glucocorticoids were tapered. The 30-mg brepocitinib group showed clinical benefit and greater glucocorticoid tapering. What is the most important safety concern? Serious infection risk is important. The FDA label also contains warnings and precautions regarding malignancy, major adverse cardiovascular events and thrombosis. What should NEET-PG and INI-CET students remember? Brepocitinib → oral TYK2-JAK1 inhibitor → adult dermatomyositis. Remember the 30-mg once-daily dose […]

Medicine, Medicine classes

Must know Target BP values in neuro-emergencies

This is a must know topic that is asked in UPSC CMS, NEET PG and INICET examinations. Go through this mini blog with approximate read time of 3 minutes and remember each line. Condition Target Remarks SAH SBP < 140-160 For raised ICP: Keep CPP > 60 Prevent re-bleeding while maintaining cerebral perfusion. Spontaneous ICH SBP -140/90 Reduces hematoma expansion Acute Ischemic Stroke (Thrombolysis Candidate) Pre-lysis: SBP < 185, DBP < 110 Post-lysis (24h): SBP < 180, DBP < 105 Reduces risk of ICH due to Thrombolytics Acute ischemic Stroke (No Thrombolysis) If SBP > 220 or DBP > 120 ↓BP by -15% in 24h Permissive HTN supports penumbra perfusion. Avoid rapid/larger drops.   Hypertensive Encephalopathy ↓ MAP by 20-25% in 1st hour, then gradual Symptoms improve with controlled reduction. Traumatic Brain Injury SBP 100  CPP 60-70 Keep CPP > 60 mmm Hg if ICP monitor available Aortic Dissection HR < 60 bpm  SBP 100-120 Reduce shear stress. Treat pain/anxiety first. First-line: β-blockers (Labetalol, Esmolol), First-line agents (neuro HTN): Nicardipine and Labetalol Avoid: Nitroprusside, Nitroglycerin NTG may be required if pulmonary edema present due to cardiac comorbidity and needs individual Now attempt an MCQ to test your knowledge For more such interesting topics keep visiting this website run by Dr Marwah who is a national level faculty for NEET PG and INICET examination.

INICET, Medical, Medicine classes, NEET PG

Hypokalemic vs. Hyperkalemic periodic paralysis – High Yield NEET PG & INI – CET guide

Why This Topic is Important for NEET PG & INI-CET Periodic paralysis disorders are commonly tested in NEET PG and INI-CET. A solid grasp of hypokalemic and hyperkalemic periodic paralysis will help in answering questions correctly. These conditions involve ion channel activity  affecting muscle function, leading to temporary paralysis. Let’s break it down in a high-yield, exam -focused manner. What is periodic paralysis? Periodic paralysis refers to rare neuromuscular disorders characterized by episodes of muscle weakness or paralysis triggered by fluctuation in serum potassium levels.  The two main types are mentioned in the tabular format highlighting key differences. Mnemonic to remember “HYPO has HIGH triggers, HYPER has Low Triggers” HYPO Kalemic Paralysis = HIGH Sugar & Carb intake causes an attack . HYPER Kalemic paralysis = LOW Food intake (Fasting) triggers the episode. Key differences – High – Yield Table Feature Hypokalemic Periodic Paralysis Hyperkalemic Periodic paralysis Cause Mutation in CACNA1S/SCN4A gene Primary answer as calcium channel defect Mutation in SCN4A gene Primary answer as sodium channel defect Serum potassium during attack Low (<3.5 mEq/L) High (>5.0 mEq/L) Triggers High -carb meals, exercise, stress Fasting, rest after exercise Onset Teenage years (10-20 years) Early childhood Duration of Attack Hours to days Minutes to hours Reflexes Reduced Normal Treatment Potassium supplementation, avoiding triggers Glucose, diuretics (thiazides)   Clinical cases to remember Hypokalemic Periodic Paralysis Hyperkalemic Periodic Paralysis A 15-year-old male wakes up with sudden muscle weakness after eating a large pizza and soda the previous night Blood tests show low serum potassium ( 2.5 mEq/L) A 6-year-old child experiences muscle weakness after skipping breakfast. Symptoms resolve spontaneously after a few hours. Blood tests show elevated potassium ( 5.6 mEq/L).   Diagnosis & Investigations Serum potassium levels during an attack Electromyography (EMG): Shows myotonic discharges in Hyper PP Genetic testing: Confirms mutations in SCN4A (Hyper PP) and CACNA1S/SCN4A (Hypo PP) Exercise Test: Potassium levels drop in Hypo PP and rise in Hyper PP   Treatment Approach – High Yield Table Condition Acute attack Management Long-Term prevention Hypokalemic PP Oral /IV potassium Avoid high-carb meals, Acetazolamide Hyperkalemic PP Glucose + insulin, diuretics Low potassium, diet, acetazolamide   Exam Pearls – Must – Know for NEET PG & INI- CET Hypokalemic PP is often linked to thyrotoxic periodic paralysis – commonly seen in Asian populations. Hyperkalemic PP is associated with myotonia (delayed muscle relaxation after contraction). Acetazolamide is used in both conditions as it stabilizes ion channels but can worsen type 2 RTA.   📌Related High – Yield Topics to Read click on this link https://marwahmedicine.com/newsite/blogs/ Suggested reading for doctors sitting for NEET PG and INICET examination from these blog posts 📌Barrter vs. Gitelman syndrome 📌 Renal Tubular Acidosis 📌 Electrolyte disorders – Quick Mnemonics& Cases

FMGE, INICET, Medicine, Medicine classes, NEET, NEET PG, NEETPG2024

Tricuspid Regurgitation

#CausesofTricuspid #TricuspidRegurgitation #TricuspidPrevent Causes of Tricuspid Regurgitation Mnemonic: Functional REP-C Functional dilatation of tricuspid annulus due to RVF R: Rheumatic heart disease, Radiation E: Endomyocardial fibroelastosis and Ebstein anomaly (Lithium teratogenicity) P: Pulmonary artery hypertension severe causing RVF P: Pacing lead induced damage C: Carcinoid syndrome   Clinical features Effort intolerance due to less pulmonary blood flow Visible neck pulsations Abdominal fullness and reduced appetite Examination findings Lancisi sign / cv wave/ prominent v waves Absent x descent Prominent y descent (Contrast with blunted Y of tricuspid stenosis) Pulsatile liver (Systolic pulsations) Pan-systolic murmur that increases on deep inspiration ( carvallo sign) Work up ECG shows -Right axis deviation -Right atrial enlargement of P pulmonale -WPW syndrome can co-exist in Ebstein anomaly and hence ECG findings of delta  wave with short PR interval can be present CXR shows RV enlargement IOC is trans-esophageal echocardiography Doppler shows reversed systolic flow in liver Management Salt restricted diet Diuretics Tricuspid valve repair (TVRp) Tricuspid valve replacement (TVR)

Medicine classes, NEET PG, NEETSS, NExT, NExT Exam

MULTIFOCAL ATRIAL TACHYCARDIA

#NEETPG #NEETSS #USMLE 2 min read Multifocal Atrial Tachycardia: A Diagnostic and Therapeutic Challenge Multifocal atrial tachycardia (MAT) presents a unique challenge for clinicians. Its variable presentation, non-specific symptoms, and potential for mimicking other arrhythmias necessitate a high index of suspicion and a nuanced approach to diagnosis and management. Clinical Presentation: While some patients with MAT may be asymptomatic, common presentations include: Palpitations Dyspnea Lightheadedness Fatigue The hallmark ECG finding in MAT is multiple P wave morphologies preceding each QRS complex, often with a short P-R interval. However, differentiating MAT from sinus tachycardia with varying P wave morphology or atrial flutter with conduction block requires careful analysis. Unveiling the Underlying Cause: Identifying the underlying condition driving MAT is crucial for optimal management. Here are some key areas to consider: Pulmonary Disease: Chronic obstructive pulmonary disease (COPD), acute respiratory failure, and pulmonary embolism can all trigger MAT. Cardiac Insults: Myocarditis, pericarditis, and coronary artery disease can create a substrate for MAT. Electrolyte Imbalances: Derangements in potassium, magnesium, or calcium can disrupt electrical conduction. Other: Stimulant use, upper GI bleed, and even thyrotoxicosis can be associated with MAT.   Therapeutic Strategies: Treatment for MAT revolves around addressing the underlying cause: Pulmonary Optimization: Managing COPD, treating respiratory failure, and anticoagulation for pulmonary embolism are crucial. Electrolyte Correction: Restoring electrolyte balance is essential for normal cardiac conduction. Medications: Calcium channel blockers, beta-blockers, or amiodarone can help control heart rate and rhythm. Catheter Ablation: When medications fail or the arrhythmia is highly symptomatic, catheter ablation targeting the ectopic foci in the atria can be curative.

Medicine, Medicine classes, NEET PG, NExT, NExT Exam

Revised Mayo Criteria for TTCM

#NEETSS #CARDIOLOGY #MEDICINELECTURES 2 min read The revised Mayo Clinic criteria for Takotsubo cardiomyopathy were developed to improve the accuracy of diagnosing this condition. These criteria were proposed by Mayo Clinic researchers and have been widely adopted in clinical practice. The revised Mayo Clinic criteria for TTCM include:   Transient Hypokinesis, Akinesis, or Dyskinesis of the Left Ventricular Mid-Segments with or without Apical Involvement: Echocardiography or other imaging modalities should demonstrate transient wall motion abnormalities in the left ventricle, typically involving the mid-segments with or without apical involvement. The characteristic appearance is akin to a Japanese octopus trap (Takotsubo). Absence of Obstructive Coronary Artery Disease or Angiographic Evidence of Acute Plaque Rupture: Coronary angiography should reveal no significant obstructive coronary artery disease or evidence of acute plaque rupture that would explain the extent of myocardial dysfunction observed. New ECG Changes (ST-Segment Elevation and/or T-Wave Inversion) or Troponin Elevation: ECG findings may mimic those of acute coronary syndrome, such as ST-segment elevation or T-wave inversion, but without corresponding coronary artery occlusion. Elevated levels of cardiac biomarkers, such as troponin, may also be present, indicating myocardial injury. Absence of Pheochromocytoma and Myocarditis: Other potential causes of acute myocardial dysfunction, such as pheochromocytoma or myocarditis, should be considered and excluded based on clinical assessment and diagnostic tests. Recovery of Left Ventricular Dysfunction Within a Short Time Frame: The characteristic feature of TTCM is the transient nature of left ventricular dysfunction, with recovery typically occurring within weeks to months.

Medicine, Medicine classes, NEET PG, NExT, NExT Exam

Allergic bronchopulmonary Aspergilloma

#NEETPG #INICET #FMG #MCISCREENING #MARWAHMEDICINE #PREPLADDERMEDICINE 2 min read Telegram link: https://t.me/realmarwahmedicine  Mnemonic to remember the key features of Allergic Bronchopulmonary Aspergillosis (ABPA): “SPADE.” S: Serum Ig E elevation > 1000 IU/ml  is a  hallmark feature of ABPA due to allergic sensitization to Aspergillus. Alternatively Skin test reactivity can be used for diagnosis confirmation. P: Pulmonary findings like infiltrates on CXR and CT scan shows Central Bronchiectasis and Positive Precipitins to aspergillus A: Asthma association though in some cases patient may has cystic fibrosis. Aspergillus colonization of airways is responsible for this presentation. D: Dyspnea: Dyspnea, or shortness of breath, is a common symptom of ABPA, often accompanied by coughing, wheezing, and sputum production. E: Eosinophilia For management of ABPA, itraconazole and systemic steroids are used. Alternatively, Omalizumab is used. The rationale for using itraconazole is to reduce antigenic stimulation.   Comparison of ABPA versus Acute eosinophilic pneumonia   ABPA Allergic interstitial pneumonitis Etiology Allergic reaction to the fungus Aspergillus Unknown, smoking initiation, Vaping Clinical Presentation Brown sputum plugs in an asthmatic or cystic fibrosis Acute respiratory distress, fever, cough, and shortness of breath. The onset is rapid, often within a few days. Chest X-rays may show diffuse infiltrates.   Labs Elevated serum IgE levels, eosinophilia, and positive Aspergillus-specific IgE and IgG antibodies Eosinophilia and BAL showing eosinophils Treatment Steroids plus antifungals Steroids  

Medicine, Medicine classes, NEET PG, NExT, NExT Exam

Churg-Strauss syndrome or Eosinophilic Granulomatosis with Polyangiitis

#NEETPG #INICET #FMG #MCISCREENING #MARWAHMEDICINE #PREPLADDERMEDICINE Churg-Strauss syndrome, also known as eosinophilic granulomatosis with polyangiitis (EGPA), has peripheral eosinophilia and pulmonary eosinophilia with infiltrates on CXR. The characteristic feature of this disease is Eosinophilic vasculitis which is not seen in other diseases of lungs which have eosinophilia. A mnemonic to remember Churg-Strauss syndrome is: “CHARM”: C –Cardiac manifestation of myocarditis H –High eosinophil count with as much 75% of TLC being eosinophils A – Asthma and Allergic rhinitis history R – Renal involvement with Glomerulonephritis and Rashes with Purpura M – Mononeuritis multiplex (peripheral neuropathy) Usually, the patient will start having features of asthma and allergic rhinitis by 20-30 years of age. Lateral Peripheral eosinophilia is seen with as much as 75% of TLC being eosinophils. Eosinophils then infiltrate tissues producing neuropathy, myocarditis, eosinophilic gastroenteritis. In late forties or fifties these patients will develop fever, weight loss and malaise with myalgia.   Laboratory Findings Eosinophilia: Elevated eosinophil count in peripheral blood. Elevated Acute Phase Reactants: Such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Positive ANCA (Antineutrophil Cytoplasmic Antibodies): Although not always present, ANCA positivity, particularly perinuclear ANCA (p-ANCA), can be seen in a subset of patients. Chest X-ray: May reveal pulmonary infiltrates, nodules, or cavities CT Scan: High-resolution CT may show ground-glass opacities, interstitial fibrosis, or other pulmonary abnormalities. Biopsy Findings: Histopathological examination of affected tissues may reveal eosinophilic infiltration, vasculitis, and granulomatous inflammation. Telegram link: https://t.me/realmarwahmedicine

Medicine, Medicine classes, NEET PG, NExT, NExT Exam

HYPERSENSITIVITY PNEUMONITIS

#NEETPG #INICET #FMG #MCISCREENING #MARWAHMEDICINE #PREPLADDERMEDICINE Here is a Quick mnemonic to remember the features of Hypersensitivity pneumonitis is: FARMER’S LUNG 4 F – Fever and Breathing problems A – Acute onset on exposure to grain, Moldy hay and Silage which harbor Thermophilic Actinomycetes R – Respiratory symptoms (cough, dyspnea and Clubbing is seen too M – Malaise starting within 4 to 8 hours of antigenic exposure E – Elevated erythrocyte sedimentation rate and BAL shows lymphocytosis R – Radiographic findings (ground-glass opacities, reticulonodular infiltrates) S – Symptoms improve with removal from exposure L – Lymphocytic alveolitis U – Uncommon but can progress to chronic disease N – Noncaseating granulomas G – Granulomatous inflammation and Diagnosis is based on Clinical prediction rule 4- Type 4 hypersensitivity reaction This mnemonic can help you recall the key features associated with Hypersensitivity pneumonitis.

Medical, Medicine, Medicine classes, NEET PG

Dr. Marwah Live: Best YouTube channel for budding doctors

Medical science is one of the most widespread forms of education in the world, where the bests emerge towards becoming doctors, the saviors of lives. While it is one of the most desired professions in the world, it is also, without a doubt, one of the most difficult professions to get into.  Honestly, why wouldn’t it be when people often refer to them as mortal Gods or entrust them with all their heart for saving hundreds of lives. Therefore, the course of MBBS for budding doctors and the subsequent entrance for their PG courses are extremely challenging, to say the least. However, they need not worry, because there are materials available online that can be the live-savers of the saviors.  While there are hundreds of books available, with each weighing about a ton each, there are also interactive live sessions available online, and they are as important for the real-life experience as books are for knowledge. One such platform that helps the budding doctors and PG aspirants to further success in their careers is Dr. Marwah Live, a YouTube Channel, designed by Dr. Deepak Marwah, to aid the students to learn the concepts of the field of medical science, through live sessions, where he gives real-life visualization of the world of medicine. His sessions are moderately long, that do not bore the students with few hours of monotonous information, making their brain capacities reduce and cause mental fatigue. Dr. Deepak Marwah is a widely known academician and a clinician. He has been teaching young medical students, who are the flag-bearers of the medical science of the next generation. He trains them for their Undergraduate examination concepts and trains them for post-graduation entrances. An alumnus of the Maulana Azad Medical College in Delhi, he has been involved with academics for the last 15 years. With over 45 thousand Subscribers, his channel is one of the most student-friendly channels available in the field of medical science, with lucid lectures that aid the ease of understanding every concept by heart. Although there is no particular day in the week that he uploads the videos or goes a life, they are fairly regular and whenever they come up, it is made sure that they are delivered in the best ways possible. Dr. Marwah not only teaches the concepts of Medical Sciences with ease and depth but also provides live interactive preparatory classes for INICET aspirants, who want to join for Post Graduate (PG) courses in Medical Science, like Doctor of Medicine (MD), Masters of Surgery (MS) and so on. He provides keynotes on how to crack the examinations, increase the strike rate, and score at a level where the candidates can be in a position to choose their Post Graduate Specialization according to their own preference and design their future in the field of medical science, just how they envision it. The eligibility criteria to appear in the INICET examination is that the candidates must have acquired their previous degree and also completed one year of their mandatory rotatory internship and have acquired the certificate for the same.  Once they have qualified for eligibility to sit for the exam, they have to score over the decided cut-off in the INICET exam and then continue with the follow-up procedures for finally being admitted to their preferred specialization in the post-graduate courses of whatever their chosen degree or domain would be. Some of Dr. Marwah’s widely appreciated and viewed videos are: INICET practice Sessions Cardiorenal Syndrome Quick Revision of Internal Medicine Multisystem Inflammatory And so on. Along with these, a series on his YouTube Channel has become hugely impactful on the medical students, for its realistic approach. The series is known as Clinical Scenarios Live stream. In these videos, the real-life scenarios in the medical world are discussed with the viewers. Dr. Deepak Marwah is also very vocal about the balancing of academics and life. He emphasizes the fact that rest and sleep are two very integral parts of life in order to repair and maintain the mind and body and also get rid of the fatigue that our minds may have been affected by due to continuous pressure. He says that according to him, proper rest and sleep are directly proportional to better efficiency in any concerned field. Some of the tips that he gives in order to follow a healthier lifestyle to performing better are: Following a healthy sleep schedule Take breaks in between studying to rest your brain and take a nap Distancing from the intoxication of any kind Being physically active in daily life Besides the importance of sleep and a healthy lifestyle, Dr. Marwah is also vocal about the tips to stay motivated and emotionally healthy while the students are going through a difficult phase of examinations and have to invest a lot of time studying. According to him, psychology identifies four different types of motivation- Extrinsic motivation comes from the outer world, intrinsic motivation comes from within, introjected motivation is the voice inside us that pressurizes us, and identified motivation makes a person knows their purpose and benefits of doing a certain job. To increase motivation, Dr. Marwah suggests the following: Reinforcement Learning: Setting a positive reward for an act or behavior, or a target reached The Ulysses Pact: Planning something and being bound by the plan to perform it. The Self Talk: The internal self-conversations that motivate people to do better. It is visible that Dr. Marwah is not just a wonderful academician, but also an insightful person. The time and effort that he has put into his channel, trying to help students get hold of their dreams, is commendable. His efforts have provided a new direction to the students and helped them score their targets whilst clearing their concepts and thus, it would not be an overstatement to say that his channel is undoubtedly the best platform for budding doctors to grow and learn and open their eyes to an ocean of opportunities lying ahead for them. […]

Scroll to Top